The text has been copied to the clipboard
Back
Full-text
Journal article

Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.

  • King AJ Ardelyx Inc., Fremont, CA 94555, USA. aking@ardelyx.com.
  • Siegel M Ardelyx Inc., Fremont, CA 94555, USA.
  • He Y Ardelyx Inc., Fremont, CA 94555, USA.
  • Nie B Ardelyx Inc., Fremont, CA 94555, USA.
  • Wang J Ardelyx Inc., Fremont, CA 94555, USA.
  • Koo-McCoy S Ardelyx Inc., Fremont, CA 94555, USA.
  • Minassian NA Ardelyx Inc., Fremont, CA 94555, USA.
  • Jafri Q Ardelyx Inc., Fremont, CA 94555, USA.
  • Pan D Ardelyx Inc., Fremont, CA 94555, USA.
  • Kohler J Ardelyx Inc., Fremont, CA 94555, USA.
  • Kumaraswamy P Ardelyx Inc., Fremont, CA 94555, USA.
  • Kozuka K Ardelyx Inc., Fremont, CA 94555, USA.
  • Lewis JG Ardelyx Inc., Fremont, CA 94555, USA.
  • Dragoli D Ardelyx Inc., Fremont, CA 94555, USA.
  • Rosenbaum DP Ardelyx Inc., Fremont, CA 94555, USA.
  • O'Neill D University of Alberta, Edmonton, Alberta T6G 1C9, Canada.
  • Plain A University of Alberta, Edmonton, Alberta T6G 1C9, Canada.
  • Greasley PJ Cardiovascular and Metabolic Disease (CVMD) Translational Medicine Unit, Early Clinical Development, Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.
  • Jönsson-Rylander AC Bioscience, CVMD, IMED Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.
  • Karlsson D Bioscience, CVMD, IMED Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.
  • Behrendt M Bioscience, CVMD, IMED Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.
  • Strömstedt M Bioscience, CVMD, IMED Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.
  • Ryden-Bergsten T CVMD, IMED Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.
  • Knöpfel T Institute of Physiology, University of Zurich and National Center of Competence in Research Kidney Control of Homeostasis, CH-8057 Zurich, Switzerland.
  • Pastor Arroyo EM Institute of Physiology, University of Zurich and National Center of Competence in Research Kidney Control of Homeostasis, CH-8057 Zurich, Switzerland.
  • Hernando N Institute of Physiology, University of Zurich and National Center of Competence in Research Kidney Control of Homeostasis, CH-8057 Zurich, Switzerland.
  • Marks J Department of Neuroscience, Physiology and Pharmacology, University College London, Royal Free Campus, London NW3 2PF, UK.
  • Donowitz M Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • Wagner CA Institute of Physiology, University of Zurich and National Center of Competence in Research Kidney Control of Homeostasis, CH-8057 Zurich, Switzerland.
  • Alexander RT University of Alberta, Edmonton, Alberta T6G 1C9, Canada.
  • Caldwell JS Ardelyx Inc., Fremont, CA 94555, USA.
Show more…
  • 2018-08-31
Published in:
  • Science translational medicine. - 2018
Adult
Aged
Animals
Base Sequence
Cell Membrane Permeability
Cells, Cultured
Electric Impedance
Epithelium
Female
Gastrointestinal Tract
Healthy Volunteers
Humans
Hydrogen-Ion Concentration
Intestinal Absorption
Ions
Isoquinolines
Male
Mice
Middle Aged
Phosphates
Potassium
Protons
Rats
Sodium
Sodium-Hydrogen Exchanger 3
Sulfonamides
Tight Junction Proteins
Young Adult
English Hyperphosphatemia is common in patients with chronic kidney disease and is increasingly associated with poor clinical outcomes. Current management of hyperphosphatemia with dietary restriction and oral phosphate binders often proves inadequate. Tenapanor, a minimally absorbed, small-molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), acts locally in the gastrointestinal tract to inhibit sodium absorption. Because tenapanor also reduces intestinal phosphate absorption, it may have potential as a therapy for hyperphosphatemia. We investigated the mechanism by which tenapanor reduces gastrointestinal phosphate uptake, using in vivo studies in rodents and translational experiments on human small intestinal stem cell-derived enteroid monolayers to model ion transport physiology. We found that tenapanor produces its effect by modulating tight junctions, which increases transepithelial electrical resistance (TEER) and reduces permeability to phosphate, reducing paracellular phosphate absorption. NHE3-deficient monolayers mimicked the phosphate phenotype of tenapanor treatment, and tenapanor did not affect TEER or phosphate flux in the absence of NHE3. Tenapanor also prevents active transcellular phosphate absorption compensation by decreasing the expression of NaPi2b, the major active intestinal phosphate transporter. In healthy human volunteers, tenapanor (15 mg, given twice daily for 4 days) increased stool phosphorus and decreased urinary phosphorus excretion. We determined that tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux, an effect mediated exclusively via on-target NHE3 inhibition.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/271348
Export to…
JSON data
Dublin Core
BibTeX
RIS (Zotero, …)
Statistics
Document views: 146 File downloads:
  • Full-text: 0